172 related articles for article (PubMed ID: 20370452)
1. Mupirocin application at the exit site in peritoneal dialysis patients: five years of experience.
Aykut S; Caner C; Ozkan G; Ali C; Tugba A; Zeynep G; Taner C
Ren Fail; 2010 Jan; 32(3):356-61. PubMed ID: 20370452
[TBL] [Abstract][Full Text] [Related]
2. Effect of once-a-week vs thrice-a-week application of mupirocin on methicillin and mupirocin resistance in peritoneal dialysis patients: three years of experience.
Cavdar C; Saglam F; Sifil A; Celik A; Atay T; Gungor O; Ozder A; Gulay Z; Camsari T
Ren Fail; 2008; 30(4):417-22. PubMed ID: 18569916
[TBL] [Abstract][Full Text] [Related]
3. The effects of once- or thrice-weekly mupirocin application on mupirocin resistance in patients on continuous ambulatory peritoneal dialysis--first 6 months' experience.
Cavdar C; Zeybel M; Atay T; Sifil A; Sanlidag C; Gulay Z; Camsari T
Adv Perit Dial; 2004; 20():62-6. PubMed ID: 15384797
[TBL] [Abstract][Full Text] [Related]
4. Comparison of gentamicin and mupirocin in the prevention of exit-site infection and peritonitis in peritoneal dialysis.
Mahaldar A; Weisz M; Kathuria P
Adv Perit Dial; 2009; 25():56-9. PubMed ID: 19886318
[TBL] [Abstract][Full Text] [Related]
5. The effectiveness of mupirocin preventing Staphylococcus aureus in catheter-related infections in peritoneal dialysis.
Thodis E; Passadakis P; Panagoutsos S; Bacharaki D; Euthimiadou A; Vargemezis V
Adv Perit Dial; 2000; 16():257-61. PubMed ID: 11045306
[TBL] [Abstract][Full Text] [Related]
6. The effects of weekly mupirocin application on infections in continuous ambulatory peritoneal dialysis patients.
Zeybel M; Ozder A; Sanlidag C; Yildiz S; Cavdar C; Ersoy R; Celik A; Camsari T
Adv Perit Dial; 2003; 19():198-201. PubMed ID: 14763062
[TBL] [Abstract][Full Text] [Related]
7. Emergence of resistance in staphylococci after long-term mupirocin application in patients on continuous ambulatory peritoneal dialysis.
Cavdar C; Atay T; Zeybel M; Celik A; Ozder A; Yildiz S; Gulay Z; Camsari T
Adv Perit Dial; 2004; 20():67-70. PubMed ID: 15384798
[TBL] [Abstract][Full Text] [Related]
8. Decrease in infections with the introduction of mupirocin cream at the peritoneal dialysis catheter exit site.
Uttley L; Vardhan A; Mahajan S; Smart B; Hutchison A; Gokal R
J Nephrol; 2004; 17(2):242-5. PubMed ID: 15293524
[TBL] [Abstract][Full Text] [Related]
9. The impact of topical mupirocin on peritoneal dialysis infection in Singapore General Hospital.
Lim CT; Wong KS; Foo MW
Nephrol Dial Transplant; 2005 Oct; 20(10):2202-6. PubMed ID: 16046516
[TBL] [Abstract][Full Text] [Related]
10. Do topical antibiotics reduce exit site infection rates and peritonitis episodes in peritoneal dialysis patients? The Pan Thames Renal Audit.
Davenport A;
J Nephrol; 2012; 25(5):819-24. PubMed ID: 22241640
[TBL] [Abstract][Full Text] [Related]
11. Mupirocin for preventing exit-site infection and peritonitis in patients undergoing peritoneal dialysis.
Xu G; Tu W; Xu C
Nephrol Dial Transplant; 2010 Feb; 25(2):587-92. PubMed ID: 19679557
[TBL] [Abstract][Full Text] [Related]
12. Exit site infections: systematic microbiologic and quality control are needed.
Freitas C; Rodrigues A; Carvalho MJ; Cabrita A
Adv Perit Dial; 2009; 25():26-31. PubMed ID: 19886313
[TBL] [Abstract][Full Text] [Related]
13. Prevention of peritoneal dialysis catheter infections in Saudi peritoneal dialysis patients: the emergence of high-level mupirocin resistance.
Al-Hwiesh AK; Abdul-Rahman IS; Al-Muhanna FA; Al-Sulaiman MH; Al-Jondebi MS; Divino-Filho JC
Int J Artif Organs; 2013 Jul; 36(7):473-83. PubMed ID: 23897229
[TBL] [Abstract][Full Text] [Related]
14. Randomized, double-blind trial of antibiotic exit site cream for prevention of exit site infection in peritoneal dialysis patients.
Bernardini J; Bender F; Florio T; Sloand J; Palmmontalbano L; Fried L; Piraino B
J Am Soc Nephrol; 2005 Feb; 16(2):539-45. PubMed ID: 15625071
[TBL] [Abstract][Full Text] [Related]
15. The Effect of Exit-Site Antibacterial Honey Versus Nasal Mupirocin Prophylaxis on the Microbiology and Outcomes of Peritoneal Dialysis-Associated Peritonitis and Exit-Site Infections: A Sub-Study of the Honeypot Trial.
Zhang L; Badve SV; Pascoe EM; Beller E; Cass A; Clark C; de Zoysa J; Isbel NM; McTaggart S; Morrish AT; Playford EG; Scaria A; Snelling P; Vergara LA; Hawley CM; Johnson DW;
Perit Dial Int; 2015 Dec; 35(7):712-21. PubMed ID: 26224790
[TBL] [Abstract][Full Text] [Related]
16. Alternating Mupirocin/Gentamicin is Associated with Increased Risk of Fungal Peritonitis as Compared with Gentamicin Alone - Results of a Randomized Open-Label Controlled Trial.
Wong PN; Tong GM; Wong YY; Lo KY; Chan SF; Lo MW; Lo KC; Ho LY; Tse CW; Mak SK; Wong AK
Perit Dial Int; 2016; 36(3):340-6. PubMed ID: 27044796
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Topical Chlorhexidine and Mupirocin for the Prevention of Exit-Site Infection in Incident Peritoneal Dialysis Patients.
Htay H; Johnson DW; Wu SY; Oei EL; Foo MWY; Choo JCJ
Perit Dial Int; 2017; 37(3):266-272. PubMed ID: 28183858
[TBL] [Abstract][Full Text] [Related]
18. The impact of topical mupirocin on peritoneal dialysis infection rates in Singapore General Hospital.
Lim CT; Wong KS; Foo MW
Nephrol Dial Transplant; 2005 Aug; 20(8):1702-6. PubMed ID: 15855200
[TBL] [Abstract][Full Text] [Related]
19. Outcome and clinical implications of a surveillance and treatment program for Staphylococcus aureus nasal carriage in peritoneal dialysis patients.
Crabtree JH; Hadnott LL; Burchette RJ; Siddiqi RA
Adv Perit Dial; 2000; 16():271-5. PubMed ID: 11045309
[TBL] [Abstract][Full Text] [Related]
20. Exit-Site Dressing and Infection in Peritoneal Dialysis: A Randomized Controlled Pilot Trial.
Mushahar L; Mei LW; Yusuf WS; Sivathasan S; Kamaruddin N; Idzham NJ
Perit Dial Int; 2016; 36(2):135-9. PubMed ID: 26374836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
